Company: MDCXW
Filing Date: 2025-05-05
Form Type: 253G2
Source: 0001062993-25-008440
Chunk: 27

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-05
Form: 253G2
Chunk 27
---
 | -            |             90,257 |
| Robert J. Ciaruffoli | 75,000 | -           |       30,257 | -            | -            | -            |            105,257 |
| Frank Lavelle        | 60,000 | -           |       30,257 | -            | -            | -            |             90,257 |

<div align='center'>17</div>

| Director           |          Fees 
 earned ($)(1) | Share-based 
 Awards      
 ($)         | Option-based 
       Awards 
          ($) | Non-equity   
 incentive    
 plan         
 compensation 
 ($)          | Nonqualified 
 deferred     
 compensation 
 earnings     
 ($)          | All Other    
 Compensation 
 ($)          | Total Compensation 
                ($) |
| William L. Ashton  |        50,000 | -           |       30,257 | -            | -            | -            |             80,257 |
| Barry Fishman      |        60,000 | -           |       30,257 | -            | -            | -            |             90,257 |
| Dr. Sara R. May(2) |        30,000 | -           |       76,051 | -            | -            | -            |            106,051 |

(1)All non-executive directors were paid $50,000 annually, in quarterly installments, as compensation for Board membership in 2024. In addition, committee Chairs received an annual compensation of $10,000, other than the Chair of the Audit Committee, who received $15,000, and Mr. Ciaruffoli, as the lead director, who received an additional $10,000 per annum.

(2)Dr. Sara R. May joined the Board in June 2024.

Directors' Service Contracts

There are no arrangements or understandings between us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their service as directors of our company.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the beneficial ownership of our common shares as of April 15, 2025, by:

each person known by us to be the beneficial owner of more than 5% of our outstanding common shares;

each of our